Search results :

Imatinib

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: L01XE01

Side effects

Options: Show MedDRA Preferred Terms,   display all 26 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Neoplasm malignant 79% - 91.2% x x x x x
Haemoglobin decreased 0.5% - 80.3% 0% - 27% x x
Lethargy 11.7% - 74.9% x
Oedema peripheral 0.3% - 40.9% 0% - 14.8% x x x x
Fatigue very common, 0% - 74.9% 1.2% - 40.9% x x x x x x x x x x x x x x x x x x x
Hypoproteinaemia 0% - 31.8% x x
Skin exfoliation 7.6% - 49.8% x
Neutrophil count decreased 3.3% - 33.3% 0.9% - 6.1% x x
Abdominal pain very common, 0% - 57.2% 1.4% - 22.3% x x x x x x x x x x x x x x x x x x x
Dermatitis very common, 1.5% - 38.9% x x x x x x x x x x x x x x x x x
Diarrhoea very common, 0.464% - 70% 1.4% - 29.3% x x x x x x x x x x x x x x x x x x x
Eczema very common x x x x x x
Rash very common, 0% - 53% 0% - 12.8% x x x x x x x x x x x x x x x x x x x
Headache very common, 0% - 43.3% 0% - 20.3% x x x x x x x x x x x x x x x x x x x
Musculoskeletal pain very common, 0% - 49% x x x x x x x x x x x x x x x x x x x
Nausea very common, 0.4% - 74% 1.2% - 27.8% x x x x x x x x x x x x x x x x x x x
Muscle spasms very common, 0% - 49% 0% - 3.3% x x x x x x x
Vomiting very common, 0.5% - 58% 0.6% - 13.9% x x x x x x x x x x x x x x x x x x x
Periorbital oedema very common, 0.5% - 74.2% 0% - 14.5% x x x x x x x x x
Bone pain very common, 1.6% - 15.6% x x x x x x x x
White blood cell count decreased 0.6% - 47% 0.3% - 4.3% x x
Pain 0.7% - 45.5% x x x
Depression uncommon, 0% - 35.8% 0.6% - 6.4% x x x x x x x x x x x x
Hypoalbuminaemia 0% - 21.2% x x x
Skin toxicity 5.7% - 20.1% x
Cramp muscle very common, 0% - 62% x x x x x x x x x x x x x x x x x x x
Arthralgia very common, 0% - 40% 0.3% - 14.5% x x x x x x x x x x x x x x x x x x x
Dyspepsia very common, 0% - 27% 0% - 13% x x x x x x x x x x x x x x x x x x x
Oedema very common, 0% - 86.1% x x x x x x x x x x x x x x x x x x x
Myalgia very common, 0% - 38.8% 0.3% - 11.6% x x x x x x x x x x x x x x x x x x x
Platelet count decreased 0% - 14.1% 0% - 3.5% x x
Ascites uncommon, 3% - 15% x x x x x x x x x x x x x x x x x x x
Body temperature increased common, 0% - 42.6% x x x x x x x x x x x x x x x x x x x
Pleural effusion uncommon, 0% - 15% x x x x x x x x x x
Agranulocytosis 3.1% - 16.1% x
Lightheadedness 2.8% - 11% x
Pharyngeal mucositis 4.3% - 10% x
Dyspnoea common, 0.5% - 21% x x x x x x x x x x x x x x x x x x x
Pneumonia uncommon, 0.155% - 13% x x x x x x x x x x x x x x x x x x x
Fluid retention very common, 0% - 81% x x x x x x x x x x x x x x x x x x x
Back pain 0% - 26% 0% - 8.1% x x x x x x x x x x x x x
Sweating 2.8% - 12.7% x
Heartburn 0.5% - 11.5% x
Abdominal distension common, 0% - 19.2% 0.3% - 6.4% x x x x x x x x x x x x x x
Alopecia common, 0% - 22.3% 0% - 6.7% x x x x x x x x x x x x x x
Anorexia common, 0% - 35.8% 0% - 8.7% x x x x x x x x x x x x x x x x x x x
Asthenia common, 0% - 74.9% x x x x x x x x x x x x x x x x x x x
Conjunctivitis common, 0% - 7.6% x x x x x x x x x x x x x x
Constipation common, 0% - 16% 0.3% - 17.7% x x x x x x x x x x x x x x x x x x x
Cough common, 0% - 27% 0% - 11.3% x x x x x x x x x x x x x x x x x x x
Dizziness common, 0% - 24.4% 0.3% - 10.7% x x x x x x x x x x x x x x x x x x
Epistaxis common, 0% - 13% x x x x x x x x x x x x x x x
Flatulence common, 0% - 34% 0% - 9.6% x x x x x x x x x x x x x x x x x x
Gastrooesophageal reflux disease common x x x x x x x x x x x x x x
Haemorrhage postmarketing — 0% - 53% x x x x x x x x x x x x x x x x x x x
Hypoaesthesia common x x x x x x x
Night sweats common, 0.2% - 17% x x x x x x x x x x x x x x x x x x x
Paraesthesia common, 0% - 12.1% x x x x x x x x x x x x x x
Pruritus common, 0% - 25.8% 0% - 7.8% x x x x x x x x x x x x x x x x x x x
Erythema common x x x x x x x
Weight increased very common, 0% - 32% 0% - 11.6% x x x x x x x x x x x x x x x x x x x
Dry mouth common, 0% - 10.9% x x x x x x x x
Chills common, 3% - 11% x x x x x x x
Mouth ulceration uncommon, common x x x x x x x x x x x x x x
Generalised oedema common x x x x x x x x x x x x x x x x x x x
Dry skin common, 0% - 6.7% 0% - 5.2% x x x x x x x x x x x x x x
Joint swelling common x x x x x x x x x x x x x x
Lacrimation increased common, 0% - 18% 0% - 3.8% x x x x x x x x x x x x x x x x x x
Eyelid oedema common x x x x x x x
Vision blurred common, 0% - 11.1% 0% - 2.3% x x x x x x x x x x x x x x
Rigors common, 0% - 34% x x x x x x x x x x x x x x x x x x
Face oedema common, 0.3% - 6.8% 0% - 1.2% x x x x x x x x x x x x x x x x x x
Febrile neutropenia common x x x x x x x
Insomnia common, 0% - 19% 0% - 7.2% x x x x x x x x x x x x x x x x x x
Loose stools 0% - 12% x x x x x
Neutropenia postmarketing — 0% - 100% x x x x x x x x x
Anaemia postmarketing — 0% - 42% x x x x x x x x x x x x x x x x x x x
Influenza like illness 0% - 15.9% x
Hypokalaemia uncommon, 0.2% - 33.7% 0.6% - 2% x x x x x x x x x x x x x x x x x x x
Throat sore 0% - 11% x x x x
Pain in extremity 0.3% - 7.4% 0% - 7.2% x
Leukopenia 0.3% - 19.6% 0% - 2.6% x x x
Abdominal pain upper 0.3% - 6.2% 0% - 6.4% x
Weight decreased infrequent — 0% - 17.3% 0% - 5.2% x x x x x x x x x x x x x x
Dysgeusia common, 0% - 15% 0% - 2.9% x x x x x x x x x x x x x x x x x
Upper respiratory tract infection uncommon — 0% - 21.2% 0% - 3.5% x x x x x x x x x x x x x x x x x x
Hypocalcaemia 0.3% - 5.6% 0% - 1.7% x x
Hypoxia 0.309% - 8.7% x
Sinusitis uncommon, 0.2% - 11.4% x x x x x x x x x x x x x x
Aspartate aminotransferase increased 0% - 37.9% x x x x x x x x x x x x x x
Stomatitis uncommon, 0.6% - 16.3% 0% - 1.7% x x x x x x x
Mucosal inflammation 0% - 10.3% x
Alanine aminotransferase increased 0% - 34.3% x x x x x x x x x x x x x x
Photosensitivity reaction infrequent — 0% - 7.1% x x x x x x x x x x x x x x
Chest pain uncommon, 0.4% - 11% x x x x x x x x x x x x x x
Infection postmarketing — 0% - 53.3% x x x x x x x x x x x
Gastrointestinal haemorrhage uncommon, 0.2% - 8% x x x x x x x x x x x x x x x
Petechiae uncommon, 0% - 10% x x x x x x x x x x x x
Tumour haemorrhage postmarketing — 1% - 4% x x x x x x x x x x x x x x x x x
Ecchymosis uncommon, 0% - 11% x x x x x x x x x x x
Anxiety infrequent — 0% - 12% x x x x x x x x x x x x x x
Nasopharyngitis uncommon, 0% - 30.5% x x x x x x x x x x x x x x x x x x
Influenza uncommon, 0% - 13.8% x x x x x x x x x x x x x x x x x x
Blepharitis uncommon x x x x x x x
Cellulitis uncommon x x x x x x x
Cheilitis uncommon x x x x x x x
Conjunctival haemorrhage infrequent, common x x x x x x x x x x x x x x
Contusion uncommon x x x x x x x x x x
Libido decreased uncommon x x x x x x x
Dysphagia uncommon x x x x x x x
Dehydration infrequent, uncommon x x x x x x x x x x x x x x
Dermatitis exfoliative infrequent, uncommon x x x x x x x x x x x x x x
Eosinophilia postmarketing, uncommon x x x x x x x
Eructation uncommon x x x x x x
Oesophagitis uncommon x x x x x x x
Flushing infrequent, common x x x x x x x x x x x x x x
Folliculitis uncommon x x x x x x x
Gastritis infrequent, common x x x x x x x x x x x x x x
Gastroenteritis infrequent, uncommon x x x x x x x x x x x x x x
Gout infrequent, uncommon x x x x x x x x x x x x x x
Gynaecomastia uncommon x x x x x x x
Cardiac failure infrequent x x x x x x x
Cardiac failure congestive uncommon x x x x x x
Haematemesis uncommon x x x x x x x
Haematoma uncommon x x x x x x x
Subdural haematoma uncommon x x x x x x x
Haematuria infrequent, uncommon x x x x x x x x x x x x x x
Hepatitis uncommon x x x x x x x x x x
Herpes simplex infrequent, uncommon x x x x x x x x x x x x x x
Herpes zoster infrequent, uncommon x x x x x x x x x x x x x x
Hyperbilirubinaemia uncommon x x x x x x
Hypercalcaemia uncommon x x x x x x x
Hyperglycaemia uncommon, 0.6% - 9.8% 1.7% - 11.3% x x x x x x x x
Hypertension infrequent, uncommon x x x x x x x x x x x x x x
Hypotension infrequent — 0.927% - 10.9% x x x x x x x x x x x x x x
Hypotrichosis uncommon x x x x x x x
Jaundice uncommon x x x x x x x x
Renal failure acute uncommon x x x x x x x
Lymphopenia uncommon, 0.7% - 10.1% x x x x x x x x x
Melaena uncommon x x x x x x x
Menorrhagia infrequent, uncommon x x x x x x x x x x x x x x
Nail disorder infrequent x x x x x x x x
Palpitations uncommon, 0% - 5.2% x x x x x x x
Pancreatitis rare, uncommon x x x x x x x x x x x x x
Pancytopenia infrequent, common x x x x x x x x x x x x x x
Neuropathy peripheral infrequent — 0% - 5.9% 0% - 6.4% x x x x x x x x x x x x x x
Pharyngitis uncommon, 0% - 15% x x x x x x x x x x x x x x
Psoriasis infrequent, uncommon x x x x x x x x x x x x
Pulmonary oedema uncommon x x x x x x x x x x x x x x x x x x x
Purpura infrequent, uncommon x x x x x x x x x x x x x x
Renal failure infrequent, uncommon x x x x
Restless legs syndrome uncommon x x x x x x x
Sciatica infrequent, uncommon x x x x x x x x x x x x x x
Pigmentation skin infrequent x x x x x x x
Gastric ulcer infrequent, uncommon x x x x x x x x x x x x x x
Syncope infrequent, uncommon x x x x x x x x x x x x x x
Tachycardia infrequent, uncommon x x x x x x x x x x x x x x
Tinnitus infrequent, uncommon x x x x x x x x x x x x x x
Tremor uncommon x x x x x x x
Pollakiuria infrequent, uncommon x x x x x x x x x x x x x x
Urinary tract infection uncommon x x x x x x x
Urticaria uncommon x x x x x x x
Vertigo infrequent, uncommon x x x x x x x x x x x x x x
Rash pustular uncommon x x x x x x x
Hypophosphataemia infrequent, uncommon x x x x x x x x x x x x x x
Migraine infrequent, uncommon x x x x x x x x x x x x x x
Creatine phosphokinase increased infrequent x x x x x x x x
Scrotal oedema uncommon x x x x x x x
Lactic dehydrogenase activity increased infrequent x x x x x x x x
Bone marrow depression uncommon x x x x x x x
Eye pain uncommon x x x x x x x
Menstruation irregular uncommon x x x x x x x
Skin hyperpigmentation uncommon x x x x x x x
Leukoderma uncommon x x x x x x x
Muscle stiffness infrequent, uncommon x x x x x x x x x x x x x x
Malaise uncommon, 11.7% - 74.9% x x x x x x x
Increased appetite uncommon x x x x x x x
Decreased appetite uncommon, 0% - 10.1% x x x x x x x
Memory impairment infrequent, uncommon x x x x x x x x x x x x x x
Eye irritation uncommon x x x x x x x
Blood creatinine increased uncommon — 0% - 44.4% 0.3% - 5.8% x x x x x x x
Bullous eruption infrequent, uncommon x x x x x x x x x x x x x x
Nipple pain uncommon x x x x x x x
Erectile dysfunction uncommon x x x x x x x
Sepsis infrequent, uncommon x x x x x x x x x x x x x x
Peripheral coldness infrequent, uncommon x x x x x x x x x x x x x x
Dry eye infrequent, common x x x x x x x x x x x x x x
Increased tendency to bruise uncommon x x x x x x x
Orbital oedema uncommon x x x x x x x
Lymphadenopathy uncommon x x x x x x x
Onychoclasis uncommon x x x x x x x
Sexual dysfunction infrequent, uncommon x x x x x x x x x x x x x x
Renal pain uncommon x x x x x x x
Sweating increased uncommon, 0.2% - 14.8% x x x x x x x x
Hyperuricaemia uncommon x x x x x x x
Scleral haemorrhage uncommon x x x x x x x
Thrombocytosis uncommon x x x x x x x
Blood alkaline phosphatase increased uncommon, 0% - 16.7% 0% - 7.5% x x x x x x x
Blood creatine phosphokinase increased uncommon x x x x x x
Blood lactate dehydrogenase increased uncommon, 0% - 60.1% x x x x x x x
Pharyngolaryngeal pain uncommon, 0% - 18.1% x x x x x x x x x x x x x x x x x
Hearing impaired uncommon x x x x x x x
Breast enlargement infrequent, uncommon x x x x x x x x x x x x x x
Somnolence infrequent, uncommon x x x x x x x x x x x x x x
Cerebral haemorrhage uncommon, 0% - 1% x x x x x x x x x x x x x x x x x
Thrombocytopenia postmarketing — 0% - 97.8% x x x x x x x x x x x x x x x x x x x
Blood bilirubin increased 0% - 13.1% x x x x x x x x x x x x x x
Skin disorder 0% - 4.35% x
Retinal haemorrhage rare, uncommon x x x x x x x x x x x x x x
Macular oedema rare, uncommon x x x x x x x x x x x x x x
Phosphatase alkaline increased 0% - 5.5% x x x x x x x x x x x x x
Anaphylactic shock very rare — rare x x x x x x x x
Aplastic anaemia rare x x x x x x x x
Haemolytic anaemia rare x x x x x x x
Angina pectoris rare x x x x x x x
Angioedema rare x x x x x x x x x x x x x
Arrhythmia rare x x x x x x x
Arthritis rare x x x x x x x
Atrial fibrillation rare x x x x x x x
Blast cell crisis postmarketing x x x x
Edema cerebral postmarketing, rare x x x x x x x x x x x x x x x x
Cardiac tamponade postmarketing, rare x x x x x x x
Pleuritic pain rare x x x x x x x
Colitis rare x x x x x x x x x x x x x x
Confusional state rare x x x x x x x x x x x x x
Connective tissue disorder postmarketing x x x x x x x
Cyst postmarketing x x x x x x
Cytopenia postmarketing x x x x x x x x x x x x x x x x x x
Drug eruption postmarketing x x
Diverticulitis postmarketing, rare x x x x x x x x x x
Embolism postmarketing — uncommon x x x x x x x x x x x x x
Toxic epidermal necrolysis very rare, postmarketing x x x x x x x
Erythema multiforme rare x x x x x x x
Eye disorder postmarketing x x x x x x x
Gastrointestinal disorder postmarketing x x x x x x x
Glaucoma rare x x x x x x x x x x x x x
Cardiac arrest rare x x x x x x x
Cardiac disorder postmarketing, rare x x x x x x x
Hyperkalaemia rare x x x x x x x x x x x x x x
Hypersensitivity rare x x x x x x x x
Pulmonary hypertension rare x x x x x x x
Hyponatraemia rare, uncommon x x x x x x x x x x x x x x
Immune system disorder postmarketing x x x x
Inflammatory bowel disease rare x x x x x x x
Intestinal obstruction postmarketing — uncommon x x x x x x x x x x x x x
Chronic phase chronic myeloid leukemia postmarketing x x x x
Lichen planus postmarketing, rare x x x x x x x
Mediastinal disorder postmarketing x x x x x x x
Myopathy postmarketing, rare x x x x x x x
Fungal infection rare x x x x x x x
Myocardial infarction rare x x x x x x x
Necrosis postmarketing x x x x
Necrosis ischaemic postmarketing, rare x x x x x x x x x x
Neoplasm postmarketing, 5% - 20.8% x x x x x x x x
Nervous system disorder postmarketing x x x x x x x
Optic neuritis rare x x x x x x x
Osteonecrosis postmarketing, rare x x x x x x
Papilloedema postmarketing, rare x x x x x x x x x x x x x x x x
Pericardial effusion rare x x x x x x x x x x x x x x x x x x x
Pericarditis postmarketing, rare x x x x x x x x x x x x x
Polyp postmarketing x x x x x x
Pulmonary fibrosis rare x x x x x x x x x x x x x x
Rhabdomyolysis postmarketing, rare x x x x x x x
Convulsion rare x x x x x x x x x x x x x
Stevens-Johnson syndrome rare x x x x x x x x x x x x x x
Thrombosis postmarketing — uncommon x x x x x x x x x x x x x
Tumour lysis syndrome rare x x x x x x
Angiopathy postmarketing x x x x x x x x x x x x
Vitreous haemorrhage postmarketing, rare x x x x x x x x x x x x x
Acute febrile neutrophilic dermatosis rare x x x x x x x x x x
Hepatic failure postmarketing — 4% - 17.3% x x x x x x x x x x
Cataract rare x x x x x x x
Hepatitis cholestatic postmarketing x x x x x
Allergic cutaneous angiitis rare x x x x x x
Gastrointestinal perforation postmarketing, uncommon x x x x x x x x x
Growth retardation postmarketing x x x x x x x
Pulmonary haemorrhage rare x x x x x x x
Hypomagnesaemia rare x x x x x x x
Intracranial pressure increased postmarketing, rare x x x x x x x x x x x x x x x x
Muscular weakness rare x x x x x x x
Hepatic necrosis rare x x x x x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing x x x x x x x
Interstitial pneumonia rare x x x x x x x x
Interstitial lung disease postmarketing, uncommon x x x x x x x
Rash vesicular rare x x x x x x x x x x x x x x
Nail discolouration rare x x x x x x x
Acute respiratory failure postmarketing, uncommon x x x x x x x
Tumour necrosis postmarketing — uncommon x x x x x x x x x x x x x
Haemorrhagic ovarian cyst very rare — rare x x x x x x x
Blood amylase increased rare x x x x x x x
Acute generalised exanthematous pustulosis rare x x x x x x x x x x x x x x
Ileus postmarketing — uncommon x x x x x x x x x x x x x
Lichenoid keratosis postmarketing, rare x x x x x x x
Mental disorder x x x x x x
Bladder cancer x
Bone disorder x
Breast disorder x x x x x x
Hypoglycaemia x
Mastocytosis x
Musculoskeletal disorder x x x
Rhinitis x x x
Ulcer x x
Urinary tract disorder x x x x x x
Vasculitis x
Lower respiratory tract infection x x x
Creatinine increased 0% - 8% x x x x x x x x x x x x x
Malnutrition x x x x x x
Acute hepatic failure x x x x x x x x x x x x
Dyspnoea exertional x x x
Digestion impaired x x
Hepatotoxicity x x x x x x x x x x x x x x x
Gastrointestinal obstruction x x
Gastrointestinal stromal tumour x x
Edema of lower extremities x x x x x x x x x x x
Hepatobiliary disease x x x x x x x
Chronic eosinophilic leukaemia x x
Prostate cancer x
Haematological malignancy x x x
Drug interaction x
Skin carcinoma x
Renal cancer x
Eye oedema x x x
Infestation NOS x x x x x x
Blood and lymphatic system disorders x x x x x x
Ear and labyrinth disorders x x x x x x
Myelosuppression x x x x x x
Oedema aggravated x x x x x x x x x x x x x x
Post procedural haemorrhage x x x
Blood in stool x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

IMATINIB MESYLATE / GLEEVEC

Side effects:1
Source:FDA

IMATINIB MESYLATE / GLEEVEC

Side effects:45
Source:FDA

imatinib mesylate / Gleevec

Side effects:61
Source:FDA

IMATINIB MESYLATE / GLEEVEC

Side effects:64
Source:FDA

imatinib mesylate / Gleevec

Side effects:64
Source:FDA

imatinib mesylate / Gleevec

Side effects:66
Source:FDA

IMATINIB MESYLATE / GLEEVEC

Side effects:130
Source:FDA

imatinib mesylate / Gleevec

Side effects:143
Source:FDA

IMATINIB MESYLATE / GLEEVEC

Side effects:144
Source:FDA

IMATINIB MESYLATE / GLEEVEC

Side effects:148
Source:FDA

imatinib mesylate / Gleevec

Side effects:155
Source:FDA

imatinib mesylate / Gleevec

Side effects:166
Source:FDA

IMATINIB (IMATINIB MESYLATE) / GLEEVEC

Side effects:181
Source:Health Canada

imatinib mesilate / Glivec, Film coated tablet

Side effects:255
Source:Medsafe

imatinib / imatinib

Side effects:259
Source:EMA

imatinib / imatinib

Side effects:260
Source:EMA

imatinib / imatinib

Side effects:260
Source:EMA

imatinib / imatinib

Side effects:261
Source:EMA

imatinib as the mesylate salt. (beta crystals) / GLIVEC

Side effects:271
Source:medicines.org.au

IMATINIB

Side effects:280
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label